Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism
Male patients with hypogonadism receiving oral testosterone undecanoate 225 mg twice daily demonstrated improvements in libido and sexual frequency. Serum testosterone concentrations were within the reference range in 87% of patients without dose titration.
Authors
- Martin Miner (ORCID: https://orcid.org/0000-0001-6813-9242)
- Irwin Goldstein (ORCID: https://orcid.org/0000-0002-4117-8361)
- M Khera
- Shelby M. King
- Adrian S. Dobs (ORCID: https://orcid.org/0000-0003-1041-6061)
- Jed Kaminetsky
- Christina Wang (ORCID: https://orcid.org/0000-0002-8231-792X)
- Culley C. Carson
- Nachiappan Chidambaram
Institutions
- University of North Carolina at Chapel Hill (US)
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Pomerado Hospital (US)
- Johns Hopkins Medicine (US)
- Miriam Hospital (US)
- UCLA Medical Center (US)
- Manhattan Scientifics (United States) (US)
- Manhattan Medical Research (US)
- Lipocine (United States) (US)
- Antares Pharma (United States) (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- Andrology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1111/andr.13747
- Citations
- 7
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Antares Pharma
- Halozyme